September 1, 2020 – TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452
TRACER Europe B.V., a Clinical Research Organization (CRO) specializing in fast-track solutions for testing innovative biologic medicines, announced that it will support Akston Biosciences in the Phase 1 clinical testing in the Netherlands of Akston’s lead COVID-19 vaccine candidate, AKS-452. TRACER will provide regulatory services, oversight of local manufacturing contractors as well as Phase 1 Study preparation and clinical site management. Go van Dam, CEO of TRACER, emphasized, “At TRACER we fully understand the urgency for a fast-track development and clinical evaluation of innovative SARS-CoV-2 vaccines. We are highly motivated to support the Akston team to move AKS-452 rapidly into the clinic to test its safety and efficacy.”
Click here to view the full press release.